Difference between revisions of "Part:BBa K3704005"
(→Engineering Success) |
|||
(4 intermediate revisions by one other user not shown) | |||
Line 2: | Line 2: | ||
__NOTOC__ | __NOTOC__ | ||
<partinfo>BBa_K3704005 short</partinfo> | <partinfo>BBa_K3704005 short</partinfo> | ||
+ | |||
+ | <partinfo>BBa_K3704005 SequenceAndFeatures</partinfo> | ||
+ | |||
Composite part BBa_K3704005 consists of a coding sequence of firefly luciferase under the control of glucocorticoid response element (GRE). Luciferase can catalyze the oxidation of luciferin to oxyluciferin. During the oxidation of luciferin, it will emit bioluminescence. Glucocorticoid receptor (GR) belongs to the steroid hormone receptor subclass of nuclear receptors, which controls physiological processes by activating and inhibiting specific target genes (PMID: 15379669). The ligand-activated receptor dimer activates gene expression by binding to GRE in the promoter region of the glucocorticoid regulatory gene. BBa_K3704001 forms a reporting system which is regulated by GR agonist (increases the fluorescence value) and GR antagonist (reduces the fluorescence value that is stimulated by GR agonist). | Composite part BBa_K3704005 consists of a coding sequence of firefly luciferase under the control of glucocorticoid response element (GRE). Luciferase can catalyze the oxidation of luciferin to oxyluciferin. During the oxidation of luciferin, it will emit bioluminescence. Glucocorticoid receptor (GR) belongs to the steroid hormone receptor subclass of nuclear receptors, which controls physiological processes by activating and inhibiting specific target genes (PMID: 15379669). The ligand-activated receptor dimer activates gene expression by binding to GRE in the promoter region of the glucocorticoid regulatory gene. BBa_K3704001 forms a reporting system which is regulated by GR agonist (increases the fluorescence value) and GR antagonist (reduces the fluorescence value that is stimulated by GR agonist). | ||
Line 10: | Line 13: | ||
===Engineering Success=== | ===Engineering Success=== | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
Functional verification of the GRE-Fluc reporting system | Functional verification of the GRE-Fluc reporting system | ||
− | In order to test the function of the GRE-Fluc reporting system, GRE-Fluc containing plasmid and another two plasmids which produce GR (part BBa_K3704002) and Renilla luciferase (BBa_K3522012, used as an internal reference gene to provide a unified baseline for experiments), respectively, were co-transfected into HEK293T cells. With | + | In order to test the function of the GRE-Fluc reporting system, GRE-Fluc containing plasmid and another two plasmids which produce GR (part BBa_K3704002) and Renilla luciferase (BBa_K3522012, used as an internal reference gene to provide a unified baseline for experiments), respectively, were co-transfected into HEK293T cells. With addition of GR agonist (Dexamethasone, Dex) into the cell culture, significant value of luciferase activity was detected (Figure 1). While, in the presence of Dex and a GR antagonist (Mifepristone, Mife), the luciferase activity reduced to a value similar to the blank control (DMSO). |
[[File:T--ECNUAS-BBa_K3704000 Fig 4.png|500px|thumb|center|Figure 1. Relative luciferase activity in the presence of GR agonist (Dexamethasone, Dex) and GR antagonist (Mifepristone, Mife).]] | [[File:T--ECNUAS-BBa_K3704000 Fig 4.png|500px|thumb|center|Figure 1. Relative luciferase activity in the presence of GR agonist (Dexamethasone, Dex) and GR antagonist (Mifepristone, Mife).]] |
Latest revision as of 08:26, 27 October 2020
GRE-F luc
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21INCOMPATIBLE WITH RFC[21]Illegal BglII site found at 1694
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
Composite part BBa_K3704005 consists of a coding sequence of firefly luciferase under the control of glucocorticoid response element (GRE). Luciferase can catalyze the oxidation of luciferin to oxyluciferin. During the oxidation of luciferin, it will emit bioluminescence. Glucocorticoid receptor (GR) belongs to the steroid hormone receptor subclass of nuclear receptors, which controls physiological processes by activating and inhibiting specific target genes (PMID: 15379669). The ligand-activated receptor dimer activates gene expression by binding to GRE in the promoter region of the glucocorticoid regulatory gene. BBa_K3704001 forms a reporting system which is regulated by GR agonist (increases the fluorescence value) and GR antagonist (reduces the fluorescence value that is stimulated by GR agonist).
Contribution and Biology
Composite part BBa_K3704005 consists of a coding sequence of firefly luciferase under the control of glucocorticoid response element (GRE). Luciferase can catalyze the oxidation of luciferin to oxyluciferin. During the oxidation of luciferin, it will emit bioluminescence. Glucocorticoid receptor (GR) belongs to the steroid hormone receptor subclass of nuclear receptors, which controls physiological processes by activating and inhibiting specific target genes (PMID: 15379669). The ligand-activated receptor dimer activates gene expression by binding to GRE in the promoter region of the glucocorticoid regulatory gene. BBa_K3704001 forms a reporting system that is regulated by GR agonist (increases the fluorescence value) and GR antagonist (reduces the fluorescence value that is stimulated by GR agonist).
Engineering Success
Functional verification of the GRE-Fluc reporting system In order to test the function of the GRE-Fluc reporting system, GRE-Fluc containing plasmid and another two plasmids which produce GR (part BBa_K3704002) and Renilla luciferase (BBa_K3522012, used as an internal reference gene to provide a unified baseline for experiments), respectively, were co-transfected into HEK293T cells. With addition of GR agonist (Dexamethasone, Dex) into the cell culture, significant value of luciferase activity was detected (Figure 1). While, in the presence of Dex and a GR antagonist (Mifepristone, Mife), the luciferase activity reduced to a value similar to the blank control (DMSO).